S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Castle Biosciences (CSTL) Competitors

$20.17
+0.87 (+4.51%)
(As of 12/8/2023 ET)
Compare
Today's Range
$19.12
$20.22
50-Day Range
$12.19
$20.17
52-Week Range
$9.26
$29.59
Volume
200,107 shs
Average Volume
367,685 shs
Market Capitalization
$542.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.29

CSTL vs. CELC, FLGT, VRDN, HHLA, NVTA, BDSX, VCYT, RNA, PETQ, and EHAB

Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Celcuity (CELC), Fulgent Genetics (FLGT), Viridian Therapeutics (VRDN), HH&L Acquisition (HHLA), Invitae (NVTA), Biodesix (BDSX), Veracyte (VCYT), Avidity Biosciences (RNA), PetIQ (PETQ), and Enhabit (EHAB). These companies are all part of the "medical" sector.

Castle Biosciences vs.

Celcuity (NASDAQ:CELC) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Castle Biosciences had 6 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for Castle Biosciences and 2 mentions for Celcuity. Celcuity's average media sentiment score of -1.11 beat Castle Biosciences' score of -1.90 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celcuity
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
Castle Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Celcuity has a net margin of 0.00% compared to Celcuity's net margin of -39.32%. Celcuity's return on equity of -19.50% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CelcuityN/A -49.14% -35.52%
Castle Biosciences -39.32%-19.50%-17.40%

Celcuity has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

63.3% of Celcuity shares are held by institutional investors. Comparatively, 85.8% of Castle Biosciences shares are held by institutional investors. 24.3% of Celcuity shares are held by insiders. Comparatively, 7.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Celcuity has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CelcuityN/AN/A-$40.37M-$2.73-5.41
Castle Biosciences$192.01M2.83-$67.14M-$2.84-7.10

Celcuity received 241 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 66.25% of users gave Celcuity an outperform vote while only 61.11% of users gave Castle Biosciences an outperform vote.

CompanyUnderperformOutperform
CelcuityOutperform Votes
318
66.25%
Underperform Votes
162
33.75%
Castle BiosciencesOutperform Votes
77
61.11%
Underperform Votes
49
38.89%

Celcuity presently has a consensus target price of $25.00, indicating a potential upside of 67.22%. Castle Biosciences has a consensus target price of $32.29, indicating a potential upside of 60.07%. Given Castle Biosciences' higher probable upside, equities research analysts clearly believe Celcuity is more favorable than Castle Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Castle Biosciences
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Celcuity and Castle Biosciences tied by winning 8 of the 16 factors compared between the two stocks.


Get Castle Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSTL vs. The Competition

MetricCastle BiosciencesMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$542.80M$1.41B$4.62B$6.73B
Dividend YieldN/A2.00%3.00%5.95%
P/E Ratio-7.107.60130.2414.22
Price / Sales2.8397.673,061.04532.33
Price / CashN/A6.9821.6823.12
Price / Book1.333.674.734.65
Net Income-$67.14M-$166.47M$124.85M$176.73M
7 Day Performance1.00%-1.08%1.09%0.80%
1 Month Performance12.31%7.69%7.13%7.13%
1 Year Performance-17.37%-5.40%11.21%7.60%

Castle Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELC
Celcuity
2.2812 of 5 stars
$14.35
+2.6%
$23.00
+60.3%
+96.4%$347.27MN/A-5.2645Analyst Report
Negative News
Gap Up
FLGT
Fulgent Genetics
2.3721 of 5 stars
$27.55
-0.2%
$36.50
+32.5%
-28.2%$816.31M$618.97M-12.871,012Analyst Report
VRDN
Viridian Therapeutics
1.7007 of 5 stars
$15.66
-1.6%
$40.29
+157.3%
-28.1%$823.56M$1.77M-3.0786
HHLA
HH&L Acquisition
0 of 5 stars
$10.67
flat
N/A+6.1%$176.91MN/A-76.21N/APositive News
NVTA
Invitae
1.7103 of 5 stars
$0.51
-3.8%
$1.00
+95.4%
-76.6%$152.96M$481.58M-0.101,700Gap Up
BDSX
Biodesix
2.1894 of 5 stars
$1.50
+2.7%
N/A+18.7%$135.72M$38.21M-1.67245Analyst Report
Gap Up
VCYT
Veracyte
1.8939 of 5 stars
$25.78
-2.2%
$30.20
+17.1%
-6.8%$1.88B$343.15M-37.36787Negative News
RNA
Avidity Biosciences
1.679 of 5 stars
$7.08
+14.9%
$38.17
+439.1%
-22.9%$524.63M$9.22M-2.37186Gap Up
High Trading Volume
PETQ
PetIQ
2.2321 of 5 stars
$17.79
-1.9%
$29.33
+64.9%
+58.7%$523.56M$921.51M42.361,888Positive News
EHAB
Enhabit
1.3673 of 5 stars
$10.48
+0.7%
$14.29
+36.3%
-24.6%$525.36M$1.08B-7.8210,000

Related Companies and Tools

This page (NASDAQ:CSTL) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -